What is Zangjingwu s contribution to innovative drugs in China?

Zang Jingwu: I would like to say from the perspective of R&D, in addition to the opportunities, what are the challenges of making innovative antibodies? These challenges also need to be carefully considered, as they determine whether these innovative antibodies can go to the clinic.

And the real purpose of our innovative drugs is to solve clinical problems.

There are two key bottlenecks in the whole new drug development process:

The first bottleneck is the target, determining what target to do what kind of project is the key, if the first step is wrong, the subsequent steps will be wrong.

The second bottleneck is how to verify the efficacy and safety of a preclinical molecule in clinical trials.

Regarding the first bottleneck, we actually have a lot of target selection, through genetic research, we know that there are almost 30,000 genes, of which 3,000 proteins can be used as drug targets, and now we are about 700-800 already known, and there is still a lot of room for this.

Zang Jingwu established Tianjing Company in 2015.

In 2017, it completed the financing of US dollars and established more than 10 biologics pipelines

In 2018, the company will complete the second round of financing of 100 million US dollars

Chinese people are still more dependent on foreign new drugs many times, if Zang Jingwu can really do a good job of domestic innovative drugs, it is really a great contribution, I remember I have seen him say about tumor immunity before, I hope to achieve it as soon as possible, China needs such talents.

It summarizes several scientists who used to be the leaders of the R&D centers of multinational pharmaceutical companies in China, and now have opened a new chapter in their lives in Zhanghui Zaochai Jiang.

1.Lingshi Tan is the founder of dMed Biopharma.

Former Deputy President of Pfizer R&D and former General Manager of Pfizer China R&D Center.

Lingshi Tan was the founding general manager of Pfizer's global R&D in China, and now he is the founder of dMed Therapeutics, a CRO company that serves innovative drug research and development.

2.Chen Li is the founder of Hua Medicine.

Former Chief Scientist of Roche R&D (China).

Chen Li is the first scientist to return to China from a multinational pharmaceutical company to set up a R&D center in China, and he is also a typical representative of the first to leave a multinational pharmaceutical company and choose to start his own business.

3.Jinsong Wang, CEO of Harbour BioMed

Former President of Sanofi China R&D Center.

Wang Jinsong has served as the president of Sanofi's China R&D Center and Asia-Pacific Translational Medicine for a long time, and has attracted much attention in the field of domestic pharmaceutical R&D. In 2008, Sanofi officially established a R&D center in China.

4.Zang Jingwu is the founder of Tianjing Biotech.

Former Senior Vice President of GSK and former head of China R&D Center.

Jingwu Zang was the Senior Vice President of GSK and the President of GSK China R&D Center, where he presided over the establishment of GSK China R&D Center and was responsible for the full research and development of the company's innovative neurological drugs. In 2013, Jingwu Zang left GSK and then joined Simcere Pharmaceuticals as the Chief Scientific Officer of Simcere Pharmaceutical, and led the innovative drug Baijiahui, responsible for the evaluation, research and development, and investment of innovative drug projects.

5.Jiang Ningjun is the CEO of CStone Pharmaceuticals.

Former President of Sanofi Asia Pacific R&D Center.

In July 2016, the news that Jiang Ningjun was appointed as the CEO of CStone Pharmaceuticals came out, and at the same time, a series A financing of 100 million US dollars (about 100 million yuan) was announced, which attracted widespread attention in the industry.

Now the situation of domestic innovative drugs is very good, and a large number of Henglun talents have flowed into the field, and several of the people listed upstairs have worked in foreign companies and then returned to China to start their own businesses.

It's not very clear about the industry, it sounds amazing.